https://scholars.lib.ntu.edu.tw/handle/123456789/580412
標題: | Recent advances in therapy for gastric cancer | 作者: | KUN-HUEI YEH ANN-LII CHENG |
公開日期: | 2004 | 卷: | 103 | 期: | 3 | 起(迄)頁: | 171-185 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Gastric cancer is the fourth leading cause of death from cancer in Taiwan. Complete surgical resection is the only potentially curative treatment for gastric cancer. Randomized trials have failed to show the superiority of D2 over D1 dissection, and comparisons showing higher survival rates following more extensive surgery in Japan may have been influenced at least in part by the fact that D1 dissection underestimates disease stage in Western populations. No studies have shown convincing evidence of a survival benefit from adjuvant chemotherapy. A regimen of postoperative 5-fluorouracil (5-FU)-based chemoradiotherapy can improve disease-free and overall survival compared with surgery alone. Inadequate lymph node dissection for local control is a major concern. For advanced disease, HDFL (weekly 24-hour infusion of high-dose 5-FU and leucovorin)-based 'doublet' chemotherapy forms a cornerstone of combination chemotherapy in gastric cancer, but the effect on prolonged median survival is minimal. A 'sequential' non-cross-resistant strategy may be useful to prolong overall survival in patients with advanced gastric cancer. There are indications that preoperative neoadjuvant chemotherapy or chemoradiotherapy may increase the resectability of tumors and reduce the risk of postoperative recurrence. In the future, substantial improvements of treatment outcome will likely depend on the integration of novel, molecularly targeted agents into multimodality treatment strategies for all stages of gastric cancer. Further clinical research is mandatory to develop optimal therapies for gastric cancer. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-3142663465&partnerID=40&md5=aa79c5f223d84414143d581a05b8bd40 https://scholars.lib.ntu.edu.tw/handle/123456789/580412 |
ISSN: | 0929-6646 | SDG/關鍵字: | 5 chloro 2,4 dihydroxypyridine plus oxonate potassium plus tegafur; antineoplastic agent; capecitabine; cisplatin; cyclin D1; dihydropyrimidine dehydrogenase; docetaxel; doxorubicin; epidermal growth factor receptor; epidermal growth factor receptor 2; epirubicin; etoposide; Fas antigen; FAS ligand; fluorouracil; folinic acid; glutathione; irinotecan; methotrexate; mitomycin C; multidrug resistance protein 1; oxaliplatin; paclitaxel; platelet derived growth factor A; protein bcl 2; protein p53; thymidylate synthase; transforming growth factor beta; UFT; unindexed drug; antineoplastic agent; advanced cancer; antineoplastic activity; blood toxicity; bone marrow suppression; cancer mortality; cancer patient; cancer recurrence; cancer risk; cancer staging; cancer survival; clinical trial; diarrhea; drug blood level; drug half life; drug targeting; enzyme inhibition; gastrointestinal symptom; hand foot syndrome; human; Japan; leukopenia; lymph node dissection; nausea; population research; postoperative period; preoperative period; review; stomach cancer; survival rate; Taiwan; treatment outcome; vomiting; drug resistance; multimodality cancer therapy; stomach tumor; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance; Humans; Stomach Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。